Corcept Therapeutics Incorporated
DE ˙ DB ˙ US2183521028
63,98 € ↑2,18 (3,53%)
2026-06-04
DEL PRIS
SecurityDE:HTD / Corcept Therapeutics Incorporated
InstitutionComerica Bank
Latest Disclosed Ownership34,737 shares
Latest Disclosed Value $ 1,208,852
Comerica Bank reports 5.81% decrease in ownership of HTD / Corcept Therapeutics Incorporated

On January 29, 2026 - Comerica Bank filed a 13F-HR form disclosing ownership of 34,737 shares of Corcept Therapeutics Incorporated (DE:HTD) valued at $2,348,916 USD as of December 31, 2025. The entity filed a previous 13F-HR on November 14, 2025 disclosing 36,878 shares of Corcept Therapeutics Incorporated. This represents a change in shares of -5.81% during the quarter. The current value of the position is $2,222,473 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-01-29 2025-12-31 13F CORCEPT THERAPEUTICS COM 218352102 34,737 -2,141 -5.81 1,209 -60.57 0.0048
2025-11-14 2025-09-30 13F CORCEPT THERAPEUTICS COM 218352102 36,878 -3,440 -8.53 3,065 3.55 0.0115
2025-08-14 2025-06-30 13F CORCEPT THERAPEUTICS COM 218352102 40,318 2,494 6.59 2,959 -31.50 0.0115
2025-05-14 2025-03-31 13F CORCEPT THERAPEUTICS COM 218352102 37,824 -817 -2.11 4,320 121.88 0.0181
2025-02-14 2024-12-31 13F/A-1 CORCEPT THERAPEUTICS COM 218352102 38,641 600 1.58 1,947 10.63 0.0079
2025-02-14 2024-12-31 13F CORCEPT THERAPEUTICS COM 218352102 38,641 600 1,947 0.0065
2024-11-14 2024-09-30 13F CORCEPT THERAPEUTICS COM 218352102 38,041 7,200 23.35 1,761 75.65 0.0070
2024-08-15 2024-06-30 13F CORCEPT THERAPEUTICS COMMON 218352102 30,841 -1,754 -5.38 1,002 22.05 0.0042
2024-05-16 2024-03-31 13F CORCEPT THERAPEUTICS COMMON 218352102 32,595 -4,659 -12.51 821 -32.15 0.0035
2024-02-14 2023-12-31 13F CORCEPT THERAPEUTICS COMMON 218352102 37,254 203 0.55 1,210 19.92 0.0056
2023-11-21 2023-09-30 13F CORCEPT THERAPEUTICS COMMON 218352102 37,051 8,079 27.89 1,009 0.0053
2023-08-22 2023-06-30 13F CORCEPT THERAPEUTICS EQU 218352102 28,972 -23,723 -45.02 0 -100.00 0.0001
2023-01-26 2022-12-31 13F CORCEPT THERAPEUTICS COM 218352102 52,695 -16,145 -23.45 1 -99.95 0.0094
2022-10-28 2022-09-30 13F CORCEPT THERAPEUTICS COM 218352102 68,840 -8,570 -11.07 1,995 -7.38 0.0168
2022-08-02 2022-06-30 13F CORCEPT THERAPEUTICS COM 218352102 77,410 -370 -0.48 2,154 20.47 0.0177
2022-04-27 2022-03-31 13F CORCEPT THERAPEUTICS COM 218352102 77,780 -1,975 -2.48 1,788 28.73 0.0130
2022-02-18 2021-12-31 13F CORCEPT THERAPEUTICS COM 218352102 79,755 -10,142 -11.28 1,389 -17.47 0.0102
2021-11-22 2021-09-30 13F CORCEPT THERAPEUTICS COM 218352102 89,897 -3,477 -3.72 1,683 -11.51 0.0101
2021-08-26 2021-06-30 13F CORCEPT THERAPEUTICS COM 218352102 93,374 -8,087 -7.97 1,902 -21.89 0.0114
2021-04-28 2021-03-31 13F CORCEPT THERAPEUTICS COM 218352102 101,461 -3,602 -3.43 2,435 -17.40 0.0145
2021-01-28 2020-12-31 13F CORCEPT THERAPEUTICS COM 218352102 105,063 257 0.25 2,948 57.56 0.0187
2020-10-30 2020-09-30 13F CORCEPT THERAPEUTICS COM 218352102 104,806 -303 -0.29 1,871 9.03 0.0136
2020-07-31 2020-06-30 13F CORCEPT THERAPEUTICS COM 218352102 105,109 5,237 5.24 1,716 30.79 0.0132
2020-05-01 2020-03-31 13F CORCEPT THERAPEUTICS COM 218352102 99,872 3,432 3.56 1,312 4.46 0.0120
2020-02-07 2019-12-31 13F CORCEPT THERAPEUTICS COM 218352102 96,440 772 0.81 1,256 -7.10 0.0095
2019-10-31 2019-09-30 13F CORCEPT THERAPEUTICS COM 218352102 95,668 -2,501 -2.55 1,352 29.13 0.0107
2019-08-02 2019-06-30 13F CORCEPT THERAPEUTICS COM 218352102 98,169 -5,151 -4.99 1,047 -17.23 0.0084
2019-05-02 2019-03-31 13F CORCEPT THERAPEUTICS COM 218352102 103,320 1,561 1.53 1,265 6.48 0.0103
2019-02-06 2018-12-31 13F CORCEPT THERAPEUTICS COM 218352102 101,759 -460 -0.45 1,188 -5.26 0.0101
2018-11-01 2018-09-30 13F CORCEPT THERAPEUTICS COM 218352102 102,219 -41,264 -28.76 1,254 -37.11 0.0101
2018-08-01 2018-06-30 13F CORCEPT THERAPEUTICS COM 218352102 143,483 43,464 43.46 1,994 9.74 0.0139
2018-05-01 2018-03-31 13F CORCEPT THERAPEUTICS COM 218352102 100,019 2,812 2.89 1,817 -25.47 0.0130
2018-02-02 2017-12-31 13F CORCEPT THERAPEUTICS COM 218352102 97,207 97,207 2,438 0.0162
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.